Eloxx Pharmaceuticals Inc (ELOX) USD0.01
No change
- Add to watchlist
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Business summary
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Contact details
Important dates
General stock information
- Short code:
- ELOX
- ISIN:
- US29014R2022
- Market cap:
- $2.13 million
- Shares in issue:
- 3.14 million
- Sector:
- Pharmaceuticals
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.